Third- and Further-line Therapy in Advanced NSCLC Patients
Third- and Further-line Therapy in Advanced NSCLC Patients
This article systematically reviews the state-of-the-art treatments from January 2003 to June 2013. Reference selection was made from the information available in the literature on third- and further-line therapy in advanced NSCLC. In order to retrieve information on clinical trials in this setting, data were obtained from PubMed, the Cochrane Library, the American Society of Clinical Oncology (ASCO) meeting published abstracts, the European Society of Medical Oncology (ESMO) meeting published abstracts and the International Association Study Lung Cancer (IASLC) meeting published abstracts, using the keywords "chemotherapy," "target-therapy," "non small cell lung cancer" and "third-line therapy," with each item being matched with "clinical trial."
Methods
This article systematically reviews the state-of-the-art treatments from January 2003 to June 2013. Reference selection was made from the information available in the literature on third- and further-line therapy in advanced NSCLC. In order to retrieve information on clinical trials in this setting, data were obtained from PubMed, the Cochrane Library, the American Society of Clinical Oncology (ASCO) meeting published abstracts, the European Society of Medical Oncology (ESMO) meeting published abstracts and the International Association Study Lung Cancer (IASLC) meeting published abstracts, using the keywords "chemotherapy," "target-therapy," "non small cell lung cancer" and "third-line therapy," with each item being matched with "clinical trial."
Source...